Keros Corp (KROS) Cash per Single Share

Corporate emblem and logo of Keros Therapeutics (KROS)

Keros Therapeutics attracts leading biologists with ambitious goals in hematology treatment, although strict international regulations for the supply of biological substances create operational challenges. The cash per share allows the company to balance these risks, with the metric currently standing at 13.22. Ultimately, patent protection and a unique protein modulation platform provide Keros Therapeutics with a dominant position in the rare pathology sector.

Keros Therapeutics, Inc. (KROS): Cash Funds per Share from 07/04/2022 to 11/21/2026

Analytical breakdowns for Keros Therapeutics

- share price and expert price forecast:
Comprehensive company analysis:KROS (Keros Corp)
Original product of kerostx.com

For a conservative investor, the cash per share metric serves as a liquidity assessment tool, determining the portion of cash allocated to each share to cover operating expenses. In the case of Keros Therapeutics (KROS), this metric is critical, as it allows for the calculation of the company's margin of safety in the face of costly clinical trials and the high burn rate characteristic of the biotech sector.